



Central nervous system (CNS) involvement in acute lym-
phoblastic leukemia (ALL) patients can be primary or associ-
ated with a relapse. This disease location is a direct hazard for 
life and requires immediate treatment. Moreover, in the case 
of delay, persistent neurological deficits can occur.
All patients, regardless of the presence of primary CNS in-
volvement, should be treated to prevent leukaemia relapse at 
this location [1]. The development of the prevention strate-
gies has contributed over the years to a significant improve-
ment in the prognosis in ALL patients. On the other hand, the 
prevention strategies are not devoid of adverse effects. Some 
complications can be persistent and contribute to a signifi-
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cant worsening of the quality of life. Therefore, correct thera-
peutic approach must have adequate efficacy with acceptable 
toxicity.
Diagnosis
The diagnosis of CNS involvement in the course of ALL is 
based on determining the presence of leukaemic cells in the 
cerebrospinal fluid [2,3]. It requires lumbar puncture (LP) 
and the assessment of cerebrospinal fluid sediment. In doubt-
ful cases, immunophenotypic evaluation using flow cytometry 
can be useful. If there are absolute contraindications for lum-
bar puncture, it is considered sufficient to find serious neuro-
logical symptoms if they are accompanied by systemic ALL 
[2,3]. In particular, cranial nerve palsy has a special diagnos-
tic value. Central nervous system involvement can also have 
the form of localised infiltration. When neurological symp-
toms are present without any abnormalities of the cerebrospi-
nal fluid, it is indicated to perform the imaging examination 
using nuclear magnetic resonance.
In each case of new ALL diagnosis in adults, diagnostic LP 
should be performed as soon as possible. In the protocol of 
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tration in the CNS, as well as good pharmacokinetics, allow-
ing the maintenance of the therapeutic concentration above 
the mean inhibitory level for lymphoblasts for at least 2 weeks 
[10]. Its efficacy has been confirmed in clinical trials in ALL 
patients and non-Hodgkin’s lymphomas with CNS involve-
ment [8,9]. When using DepoCyte, LPs are performed every 
2 weeks. Due to their large size, the drug particles can be vis-
ible during microscopic examination. This fact should be tak-
en into account in the cytomorphological evaluation of the ce-
rebrospinal fluid.
In the MRC/ECOG study, in addition to systemic chemo-
therapy, it was allowed to irradiate the cranial base with the 
24 Gy dose, and the spinal cord with the 12 Gy dose during 
phase II induction treatment [5]. As part of the PALG proto-
col, the possibility of radiation therapy at a dose of 24–35 Gy 
is expected, with this management being rather reserved for 
patients resistant to intrathecal treatment. In the remaining 
cases, scheduled systemic chemotherapy is a priority.
Prognosis
With correct therapy, the chances to obtain complete re-
mission do not differ significantly for patients with primary 
CNS involvement compared to the other patients with ALL 
diagnosis [5,6]. In the MRC/ECOG analysis, the CR rate was 
90%, regardless of CNS involvements [5]. Similar results were 
obtained in the studies of the other working groups [6].
The prognosis as regards the chances for cure is a contro-
versial issue. In the study by Lazarus et al. [5], the chance for 
survival was significantly lower in patients with CNS involve-
ment (29% vs. 38%, p = 0.03); however, there were no sig-
nificant differences in the leukemia free survival. On the other 
hand, however, it should be emphasized that in patients with 
primary CNS involvement, isolated or mixed recurrences in-
volving the CNS have been reported significantly more often 
(11.9% vs. 5.6%; p = 0.04) [5].
Leukaemia relapse in the CNS
Incidence
Acute lymphoblastic leukaemia relapse in the CNS can be 
isolated or mixed, i.e. with accompanying infiltration of the 
bone marrow [11]. Moreover, there is a variant in which bone 
marrow relapse occurs first, then a secondary CNS involve-
ment is seen. On the other hand, the occurrence of isolat-
ed CNS involvement is usually followed by bone marrow in-
volvement. It has been shown that in patients with isolated 
CNS relapse, even if there are no signs of haematological re-
currence, leukaemia cells can be detected in the bone marrow 
at the level of minimal residual disease [12].
The historical data from the period when there was no 
CNS focused prevention show that in adults, the incidence of 
relapse at this location can be 30–50% [13,14]. In children, 
this percentage is even higher and it reaches 50–70% [1]. 
the Polish Adult Leukemia Group (PALG), the first LP is ex-
pected in the pre-treatment period. At this time, thrombo-
cytopenia can be a significant problem interfering with the 
LP procedure. In this situation, intensive substitution with 
platelet concentrate is necessary. In the opinion of the authors, 
platelet levels above 40 × 109/l, with no accompanying coag-
ulation disorders and signs of diathesis, are sufficient to per-
form a safe LP.
Primary CNS involvement
Incidence
The incidence of primary CNS involvement at the time of 
ALL diagnosis in adults is estimated at <10% [4-6]. In the 
largest study published to date, performed by the Medical Re-
search Council (MRC, United Kingdom) together with the 
Easter Cooperative Oncology Group (ECOG, United States), 
among 1508 patients with new ALL diagnosis, CNS involve-
ment was diagnosed in 77 (5%) patients [5]. In the study of 
the French group (Group for Research in Adult ALL) and the 
American group (Southwest Oncology Group) involving 572 
and 404 patients, respectively, the incidence was 7% and 5% 
[4,6]. Among 380 patients analysed in the PALG programs, 
primary CNS involvement was diagnosed in 20 (5.3%) pa-
tients. However, it cannot be ruled out that these values are 
underestimated as they only include patients referred for pro-
spective clinical studies. It should be adopted that some pa-
tients with CNS involvement do not meet the inclusion crite-
ria for study protocols due to severe clinical condition, or they 
are admitted to other departments without an established di-
agnosis of the underlying disease.
In the light of the analysis by Lazarus et al. [5], the fac-
tors predisposing to primary CNS involvement in adults diag-
nosed with ALL include: 1) high leukocytosis; 2) T-cell ALL; 
3) concomitant involvement of the mediastinum. Another 
study showed higher incidence of CNS involvement in ma-
ture B-cell ALL [7]. The presence of the above features partic-
ularly indicates the need for early LP.
Treatment
The basis of treatment in primary CNS involvement in 
adult ALL patients is intrathecal administration of cytostat-
ics in parallel with remission inducing systemic chemotherapy 
[1]. In the PALG 5-2007 protocol, methotrexate 15 mg + cy-
tosine arabinoside 40 mg + dexamethasone 4 mg are admin-
istered intrathecally. This treatment is used with high possi-
ble frequency (1–3 times a week) until the lesions completely 
regress, that is, until negative results of the cerebrospinal flu-
id cytomorphological examination are obtained in two con-
secutive tests.
An alternative for the three drug therapy is the use of cy-
tosine arabinoside in depot form (DepoCyte, Mundipharma, 
United Kingdom) [8,9]. This product has an improved pene-
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and also due to the risk of other complications, LP should be 
preceded by a correction of the platelet count and coagula-
tion parameters using the platelet concentrate or freshly fro-
zen plasma, respectively. Coagulation disorders occur very of-
ten during induction as a complication associated with the use 
of L-asparaginase.
Despite the use of the appropriate precautions, some pa-
tients experience post puncture syndrome which, if severe, 
may make the planned intrathecal therapy difficult. In this 
group of patients, it seems feasible to replace the triple thera-
py with DepoCyte (Mundipharma, Cambridge, UK), i.e. cy-
tosine arabinoside in depot form. So far, the data on the use 
of DepoCyte in prevention are isolated single-site reports 
[19,20]. There is no evidence to confirm the efficacy of this 
treatment from prospective, controlled clinical trials. These 
studies are currently being conducted in some groups, e.g. 
the GMALL, the NILG, and the Spanish group (Program 
for Study and Treatment of Malignant Hemopathies) where 
the use of DepoCyte is to allow a double reduction in LPs in 
adult ALL patients, and, as is the case of the GMALL study, 
to abandon prophylactic irradiation of the CNS. The Polish 
Adult Leukemia Group protocol provides an opportunity to 
introduce DepoCyte in place of the triple therapy, with this 
The introduction of the appropriate prevention measures al-
lowed the reduction in the CNS recurrence rate to below 5% 
in both age groups [1].
Prevention
Central nervous system relapse prevention is an important 
element of the therapeutic program in ALL patients. It in-
cludes intrathecal administration of cytostatics, irradiation of 
the cranial base and the spinal cord, and the use of drugs that 
penetrate the CNS [1]. With the today’s protocols, the CNS 
recurrence rate is relatively low. In practice, due to this fact, 
prospective randomised trials with this event as an endpoint 
are practically impossible. The guidelines for CNS lesions pre-
vention in adults are therefore mainly based on the experi-
ence of the paediatric groups and the expert opinions com-
ing from the comparative analysis of results obtained by each 
study group.
Intrathecal prevention
Intrathecal administration of cytostatics is performed in 
parallel with systemic chemotherapy at each stage of treat-
ment, i.e. during induction, consolidation and remission 
maintenance [1]. Most study groups prefer the triple therapy 
(methotrexate, cytosine arabinoside, dexamethasone), and the 
number of LPs varies and is e.g. 12 in the protocol of the Ital-
ian group (Northern-Italian Leukemia Group – NILG) and 
14 in the German group (German Multicenter ALL Working 
Group, GMALL). The Polish Adult Leukemia Group protocol 
provides the triple therapy used once in pretreatment, twice in 
the first and second phase of induction, four times during con-
solidation and every three months in the first year and every 6 
months in the second year of maintenance therapy (Fig.). The 
days of intrathecal administration of the drugs are strictly de-
termined to avoid the overlap of cytotoxicity of administered 
intrathecally and systemically drugs penetrating to the CNS.
Lumbar punctures are associated with the risk of complica-
tions, and, in particular, with post-puncture syndrome char-
acterised by headache, nausea and vomiting that may persist 
for up to two weeks after LP. The prevention of this syndrome 
consists in immobilisation in a supine position for at least 6 
hours after LP, although some neurologists recommend that 
this period should be extended to 12 h. The supine position 
also facilitates drug penetration to the cerebral ventricles [15]. 
To obtain better distribution, the cytostatics should be dis-
solved in a sufficient amount of fluid, i.e. at least 6 ml [1].
The studies of the pediatric groups have shown a corre-
lation of so-called traumatic LPs, i.e. those associated with 
blood extravasation to the spinal canal, a higher rate of CNS 
relapse and a lower chance for leukemia-free survival [16-18]. 
This effect is sometimes explained by the possibility of lym-
phoblasts penetration from the peripheral blood to the cere-
brospinal fluid, which is particularly important at the early 
stage of the disease, before CR is achieved. For this reason, 
Fig. Prophylaxis of central nervous system relapse in acute lym-
phoblastic leukemia according to the program of the Polish Adult 
Leukemia Group (PALG 5-2007). The schedule of intrathecal use of 
chemotherapy in the pre treatment, induction (depending on the 
risk factors for relapse, the patients receive one or two courses 
of induction treatment) and consolidation periods. The arrows 
indicate lumbar punctures with administration of methotrexate, 
cytarabine and dexamethasone (←) or cytarabine arabinoside in 
depot form (DepoCyte) (⇐), as provided in patients with severe 
post puncture syndrome after the first intrathecal injection
CNS irradiation










and dexamethasone, with the intention to both prevent the 
bone marrow relapse, and CNS recurrence.
The role of high-dose chemotherapy with subsequent he-
matopoietic stem cell transplant has not been clearly estab-
lished so far. However, the author’s own experience shows that 
in a significant percentage of ALL patients with prior CNS in-
volvement, the use of autologous bone marrow transplanta-
tion prevents recurrence at this location [27].
Treatment
Central nervous system  relapse treatment is similar to the 
treatment of primary involvement of this system in the course 
of ALL. As mentioned previously, isolated CNS recurrence 
almost always precedes systemic relapse [11]. The CNS-fo-
cused treatment should therefore be performed in parallel 
with intravenous chemotherapy, with consideration to cyto-
statics that penetrate the central nervous system. A partic-
ular situation are isolated CNS relapses following allogenic 
HSCT. In these patients, the graft-versus-leukemia reaction 
can allow control of the disease in the bone marrow, where-
as the CNS is the site of limited availability for immune re-
actions [28]. The treatment strategy in these patients should 
take into account close monitoring of bone marrow cell chi-
merism, and the minimal residual disease status. In justified 
cases, the treatment can be limited to the CNS, with simul-
taneous support of the graft-versus-leukemia mechanism by 
donor lymphocyte infusion, reduced immunosuppression and 
the use of interferon.
Prognosis
Although local remission can be obtained in most patients 
with CNS recurrence, the prognosis in these cases is poor due 
to concomitant or following bone marrow relapse, often che-
motherapy-resistant. In an analysis of 32 patients treated at 
the M.D. Anderson Cancer Center, diagnosed with isolated 
or mixed CNS relapse, the 4-year survival prognosis was only 
option being reserved for patients who experience symptoms 
of post-puncture syndrome following the first LP (Fig.). There 
is a precaution that DepoCyte should not be used concomi-
tantly with high dose cytosine arabinoside (HD-AraC) due to 
possible cumulative toxicity. The necessary time interval is at 
least 48 hours after HD-AraC and 14 days before HD-AraC 
[21]. The possible combination of DepoCyte with the other 
intrathecal drugs has not been established so far.
CNS irradiation
Prophylactic CNS irradiation is an effective method to pre-
vent recurrence at this location; however, it is associated with 
a significant risk of late complications, that is secondary tu-
mors, endocrinopathies, cognitive function disorders and neu-
rotoxicity [22]. As these complications mainly occur in pedi-
atric patients, it is mainly this group where attempts to aban-
don CNS irradiation or to reduce the dose have been made. In 
two consecutive studies in which CNS irradiation was aban-
doned, a relatively high, about 8.3% and 6% incidence of iso-
lated or mixed CNS relapse was seen [18,23]. Furthermore, 
in the study of the Italian group (Gruppo Italiano Malattie 
Ematologiche Maligne dell’Adulto), in adult patients, CNS 
irradiation abandonment was associated with 8% incidence 
of isolated recurrence [24]. In contrast, another study of the 
same group in which high dose dexamethasone was used (20 
mg/m2), this rate was only 2% [24]. These data suggest the 
possibility of abandoning prophylactic CNS irradiation in the 
case of intensive systemic therapy using drugs that penetrate 
to the central nervous system. However, this problem remains 
controversial and most current treatment protocols including 
the PALG 5-2007 program include CNS irradiation. On the 
other hand, there is a possibility of abandoning this procedure 
in the case of patients who are planned to undergo allogenic 
haematopoietic stem cell transplantation (HSCT) with prep-
aration including total body irradiation. As in the PALG pro-
gram most patients should be referred for the HSCT proce-
dure, the rate of prophylactic CNS irradiation can be signif-
icantly reduced.
Systemic prevention
A significant component of CNS relapse prevention is the 
use of sufficiently high doses of drugs penetrating the central 
nervous system. These include methotrexate, cytosine arab-
inoside and glucocorticosteroids [1]. The prognostic signifi-
cance of this form of therapy, as well as the minimum efficient 
doses of each cytostatic, have not been determined yet. There 
is the exception of glucocorticosteroid for which it has been 
shown in pediatric patients that the use of dexamethasone 
at a dose of 6–6.5 mg/m2/24 h is associated with a reduced 
risk of CNS relapse compared to prednisolone at a dose of 40 
mg/m2 [25,26]. Currently, most treatment protocols in adult 
ALL patients, including the PALG 5-2007 program, provide 
the use of large doses of methotrexate, cytosine arabinoside 
Table.  The most important issues in the prevention  
and treatment of central nervous system lesions  
in the course of acute lymphoblastic leukemia in adults
Early diagnosis: lumbar puncture with assessment of cerebrospinal 
fluid sediment in the pre-treatment period
If CNS involvement is diagnosed: intrathecal administration  
of cytostatics for complete elimination of the blastic cells from  
the cerebrospinal fluid + irradiation of the cranial base  
and the spinal cord concomitantly to systemic chemotherapy
If no primary CNS involvement is diagnosed: prophylactic use  
of intrathecal cytostatics in the induction-consolidation period + 
systemic use of cytostatics that penetrate to the CNS +/– 
prophylactic irradiation of the cranial base and the spinal cord
CNS – central nervous system
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6% [11]. Furthermore, in the MRC/ECOG study, in a group 
of 22 patients with isolated CNS recurrence, the 5-year sur-
vival was 0% [5].
SUMMARY
The prevention and treatment of CNS lesions are among 
the most important components of the therapeutic strategy in 
adult ALL patients. The authors’ own experience shows that 
this problem is often underestimated, and the rates of both 
LPs with intrathecal administration of cytostatics, and CNS ir-
radiation are too low. In light of the presented data, the inten-
sity of prevention seems to be critical, as a CNS relapse is asso-
ciated with very poor prognosis. Taking this into account, all 
efforts should be made to complete the entire therapy proto-
col (Tab.).
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